Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608788 | 0.82 | L3MBTL1 (0.44) | LMNAL3MBTL1MEN1KMT2ANPSR1 | |
| SCHEMBL18583592 | 0.81 | LMNA (0.47) | HPGDLMNAMEN1KMT2ANPSR1 | |
| SCHEMBL18583655 | 0.81 | LMNA (0.47) | HPGDLMNAMEN1KMT2ANPSR1 | |
| SCHEMBL18583834 | 0.81 | LMNA (0.47) | HPGDLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL14086368 | 0.80 | LMNA (0.43) | HPGDLMNAMEN1KMT2ANPSR1 | |
| SCHEMBL17722661 | 0.79 | BTN3A1 (0.46) | HPGDLMNAMEN1KMT2ANPSR1 | |
| SCHEMBL19504115 | 0.79 | BTN3A1 (0.46) | HPGDLMNAMEN1KMT2ANPSR1 | |
| SCHEMBL18666933 | 0.79 | BTN3A1 (0.46) | HPGDLMNAMEN1KMT2ANPSR1 | |
| SCHEMBL18636585 | 0.79 | BTN3A1 (0.46) | HPGDLMNA | |
| SCHEMBL25028709 | 0.77 | LMNA (0.49) | HPGDLMNAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | EMORY UNIVERSITY (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142627-A1 | MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF | DCTD, ENTPD5, PNP | HPGD 220/4885LMNA 2705/4885L3MBTL1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.